Overview of the Different Types of Immune Cells in the Intestine: The Example of its Relation with the Gut Microbiota
=====================================================================================================================

The population of gut microbiota is estimated to 100 trillion microorganisms. Thus, our body is composed of 50% of bacteria and 50% of human cells ([@B17]). Precisely, the human body encloses approximatively 4.10^13^ bacteria cells with the largest amount inside the large intestine (10^11^ bacteria cells/g of wet stools) ([@B74]). In the last estimation, almost 10 million non-redundant microbial genes have been identified in the human gut ([@B54]). The intestinal tract is subjected to an environmental pressure due to the high microbial load of the luminal content ([@B75]). Regarding microbial load, one recent article shows that it is the absolute quantity of microbes and not the proportions of microbes that really matters ([@B83]). Depending of the mode of analysis of gut microbiota population (classical relative abundance-based profiling vs. quantitative microbiome profiling), the interpretation of data could be completely different, and maybe falsely interpreted. The study of gut microbiota impacts in physiology is also complicated due to the controversial data present in the literature. In fact, results could differ depending of numerous factors that we have to take into account such as for example dietary environments, but also the composition and the activity of the gut microbes ([@B19]). To illustrate this controversy, *Prevotella copri* and its metabolites could be considered as pro- or anti-diabetic actions depending on the diet or the model used ([@B19]). Therefore, these few examples clearly highlight the fact that we are still at the beginning of the story, and we will need more time to better understand the gut microbiota and its importance in human health.

Nowadays, the impact of gut microbiota in the control of various physiological functions is proposed ([@B19]). Abnormal composition and/or activity of the gut microbiota are associated with the development of numerous pathologies such as cancer, obesity and type 2 diabetes (T2D) ([@B19]; [@B23]; [@B68]). Despite the complexity of the crosstalk, a clear link is established between inflammation and modification of the gut microbiota ([@B80]; [@B19]). Here, we will mainly introduce how gut bacteria could modulate the function of intestinal immune cells, and describe the molecular actors involved.

Intestinal bacteria are physically separated from mucosal immune system by a single epithelial cell layer, which the primary function is to absorb nutrients (small intestine) and water (colon). Mucosal immune system prevent microbial invasion and is tightly regulated. One of its major role is to avoid the development of chronic inflammation and the subsequent loss of the intestinal epithelium integrity. Microfold cells or M cells, in the specialized follicle-associated epithelium overlying Peyer Patches (PP), and isolated lymphoid follicles (ILF) are the major cell types that sample bacteria and associated antigens. Processed bacterial-derived antigens are presented locally (i.e., into the PP or ILF) or within the mesenteric lymph nodes that drain dendritic cells to initiate an adaptive immune response ([@B88]). Both effector- and regulatory-T lymphocytes scattered within the intestinal mucosa are generated in response to commensal bacterial antigens. At steady state, the number and the spectrum of effector-T lymphocytes subsets that are present within the intestinal mucosa are dependent on the host's microbiota. Any pathogen invasion, disruptions of the mucus barrier or of the intestinal epithelium integrity, and/or failure in the regulatory mechanisms of the immune response may result in mucosal inflammation ([@B9]; [@B4]). Immune mediators released upon inflammation are largely dependent on the nature of the microbes triggering the immune system ([@B56]). Intestinal epithelial cells and resident innate immune cells sense pathogens locally. The interactions between the pathogens and the pattern-recognition receptors (PRRs) expressed both by stromal and immune cells trigger rapid production of immune and microbicide mediators (e.g., cytokines, chemokines, bioactive lipids, and cell-autonomous immune effectors), which restrict pathogen growth. In parallel, dendritic cells will mature upon contact with microbe-associated molecular patterns (MAMPs) or when some factors are released by injured tissues, namely the damage associated molecular patterns (DAMPs) (i.e., a process allowing antigen presentation to T cells) ([@B56]; [@B43]). Regarding the intrinsic properties of mature dendritic cells and their soluble (e.g., cytokines, chemokines) and cellular (stromal, myeloid and lymphoid cells) immune environment, antigen-primed CD4^+^ T lymphocytes may acquire different effector functions. Indeed, viral or intracellular bacterial infections drive T lymphocyte commitment toward the Th1 phenotype, a process that relies both on the production of IL-12 and IL-18 by myeloid cells and the subsequent IFNγ released by innate lymphoid cells (ILC)1 ([@B81]; [@B11]). Th1 CD4^+^ lymphocytes produce high levels of IFNγ but also TNF-α. The clearance of extracellular bacteria and fungi mainly depends on Th17-polarized lymphocytes that produce IL-17, IL-22, IL-21, TNF-α and GMCSF. The differentiation of naïve CD4^+^ T lymphocytes into Th17 involves an environment enriched in TGFβ, IL-1β and STAT3-inducing cytokines including IL-6 and IL-23 produced by myeloid cells (e.g., dendritic cells and macrophages). IL-23 plays a key role by reinforcing Th17 functional activity and inducing production of GMCSF and TNF-α. The immune polarization of ILCs from group 2 by IL-25, IL-33 and thymic stromal lymphopoietin is a process specific to helminth parasites. This leads to a potent IL-13 release, crucial immune mediator of the anti-parasitic response ([@B64]). This frontline type 2 cytokine signaling drives the differentiation of T lymphocytes toward the Th2 phenotype, which is characterized by the synthesis of IL4, IL-5 and IL-13 cytokines, that are key to restrict helminth infections. In addition to cytokines, CD4^+^ T lymphocytes may also produce neuropeptides including opioids, serotonin and vasoactive intestinal peptide ([@B65]; [@B13]; [@B79]). Within the site of inflammation, most of these neuropeptides as well as chemokines, proteases and bioactive lipids are also produced by endothelial and epithelial cells, migrant and resident innate immune cells.

How make the link between gut microbiota, immunity and metabolic diseases? The development of metabolic disorders is clearly linked with modification of the gut microbiota population, but there are many other factors in the intestine (e.g., bioactive molecules, metabolites, endocrine cells) that are disturbed in pathological state. The diversity of the gut microbiota may not fully explain the pathologic phenotype. In fact, recent data show the importance of specific alterations that may arise at the level of the crosstalk occurring between gut microbes but also luminal and intestinal factors during metabolic disorders ([@B6]; [@B18]). One may also mention the controversy regarding microbial diversity and its potential link with the onset of inflammation. This important topic has been recently reviewed and clearly described the potential interaction between microbes and host cells *via* immune factors ([@B19]). Modifications of the balance (i.e., gut microbiota and immunity) between healthy and pathological situations participate to the establishment of a type 2 diabetic state. For example in this review ([@B19]), it is discussed that the production of the short-chain fatty acids propionate is altered during diabetes. In physiological condition, propionate can bind to GPR-43 located on intestinal lymphocytes. In pathological situations, the decrease of propionate may lead to the lower abundance of specific T cells (mucosal-associated invariant T cells and Treg) in the lamina propria of the gut. Consequently, the gut barrier function could be altered, and some pathogen-associated molecular patterns (PAMPs) can reach the circulation. This is for instance the case for the levels of lipopolysaccharides (LPS) that are significantly increased in the blood, and trigger systemic low-grade inflammation ([@B20]; [@B28]) observed in the whole body and can generate the insulin resistance state observed during diabetes ([@B25]).

Intestinal Inflammation and Type 2 Diabetes
===========================================

Obesity and associated metabolic disorders such as T2D are closely related to a « low-grade » inflammation state as described above ([@B87]). In addition to well-described tissues (liver, adipose tissue,...) ([@B49]), the intestine may presents an alteration of the gut barrier function thereby leading hyper-permeability, which is associated with a dysbiosis and in some cases with a certain degree of inflammation at the level of the gut (for review see [@B78]). Indeed, in response to a high-fat diet (HFD) that induces insulin resistance, it has been proposed that the intestinal tract may develop an inflammatory response characterized by an increase in pro-inflammatory cytokines expression such as TNF-α, IL-1β, IL-6 ([@B31]; [@B51]). Some studies have also reported an increase in myeloperoxidase activity ([@B29]) and/or a decrease in IL-18 and IL-22 expression ([@B36]; [@B86]), two cytokines involved in the intestinal barrier homeostasis and the defense against pathogens. However, it is important to note that the degree of inflammation observed during obesity and diabetes does not reach the same magnitude as the one observed during intestinal inflammatory bowel diseases or severe infection. Nevertheless, besides HFD, data also support that the genetic deletion of leptin (ob/ob) or leptin receptors (db/db) in mice leads to the development of obesity and T2D with a significant increase in pro-inflammatory cytokines (TNF-α, IL-1β, IFNγ, IL-6) in the portal vein, as well as an altered gut barrier ([@B15]). In addition to metabolic consequences, deletion of leptin receptors also alters immunological response against *Entamoeba histolytica* in mice ([@B48]) as well as in humans ([@B32]). The direct link between intestinal inflammation and metabolic disorders is observed in mice knocked-out for TLR5, a component of the innate immune system. TLR5-deficient mice exhibit a diabetic phenotype associated with intestinal inflammation including increase in pro-inflammatory cytokines (IL-1β, TNF-α) and reduction of the length of the colon, one hallmark of intestinal inflammation ([@B84]; [@B27]).

What are the "local" consequences of this gut inflammation? All mice models above display alterations of the intestinal homeostasis suggesting as close interrelation between "inflammation, microbiota and metabolism" ([@B44]). Because of this inflammatory environment, diabetic mice exhibit modifications of intestinal absorptive capacity characterized by an increase of glucose and/or lipids absorption ([@B39]; [@B66]; [@B57]) that alters the energetic metabolism. Indeed, HFD diabetic mice develop hyperglycemia and hyperinsulinemia ([@B31]), glucose intolerance and insulin resistance correlated with a decrease in mucus thickness and increased intestinal permeability ([@B21]; [@B35]). This is associated with alteration of the gut microbiota composition and activity ([@B38], [@B37]; [@B51]; [@B60]) have shown that gut colonization of germ-free mice induces a bi-phasic inflammation that participates to a bi-phasic impairment of glucose metabolism. Interestingly, recent data have also shown in humans a link between gut microbiota and the accumulation of T cells in the gut of obese people following the ingestion of a high-fat diet ([@B61]). Both the blunted insulin signaling in enterocytes and the altered localization of the glucose transporter GLUT2 in the enterocytes of obese subjects were linked to the nature of cytokines produced by mucosal T cells ([@B61]). Conversely, in obese and type 2 diabetic patients another study has shown a decreased number of mucosal-associated invariant T cells (MAIT) producing high levels of Th1 and Th17 cytokines ([@B55]).

Therefore, the molecular partners linking inflammation, gut microbiota and metabolic disorders could be multiple, but the incretin hormones may represent a real potential of interest. The intestinal tract has also the capacity to produce incretins such as Glucagon-Like Peptide-1 (GLP-1) or Gastric Inhibitory Polypeptide (GIP) in response to nutrients and/or bacterial factors ([@B22]; [@B68]). HFD and ob/ob mice display an alteration of gut endocrine system including the reduction of GIP- and GLP-1-producing cells and a decrease in proglucagon and GIP expression associated with the alteration of incretins secretion in response to an oral glucose load ([@B62]; [@B5]; [@B71]; [@B77]).

In line with these observations, we have demonstrated that prebiotic treatment in diabetic mice restores the level of GLP-1 to improve glucose metabolism ([@B24]). Moreover, a chronic exposure to TNF-α alters the release of GLP-1 in HFD mice by acting directly on GLP-1-producing cells ([@B42]). Conversely, a 2 weeks treatment with etanercept, an anti-TNF-α drug, reduces hyperglycemia and hyperinsulinemia of HFD mice. Nowadays, this tripartite concept developed in mice is considered as a potential target to treat metabolic disorders ([@B44]).

Gut-Brain Axis and Type 2 Diabetes
==================================

The gut-brain axis is shown as a major signaling pathway controlling glucose homeostasis, and its disturbance is associated with a T2D phenotype ([@B1],[@B2]). In normal conditions, glucose is detected by intestinal glucose sensors (such as SGLT1, GLUT2, TASR1/2) present on intestinal cells (enteroendocrine and brush cells, enteric glial cells and neurons) which inform the whole body from the presence of glucose *via* the release of various factors (i.e., gut hormones, neurotransmitters, metabolites) ([@B41]). Then, intestinal glucose detection generates an afferent nervous message that provokes an increase of hypothalamic nitric oxide (NO) release ([@B40]). In turn, this increase of hypothalamic NO release favors the entry of glucose in tissues *via* an activation of the autonomic nervous system ([@B40]). In db/db mice, intestinal inflammation perturbs the detection of glucose by enteric glucose sensors ([@B33]). In this case, the intestine sends an aberrant nervous message that fails to increase hypothalamic NO release ([@B33]). Accordingly, the insulin resistance state observed during T2D is linked to alteration of gut-brain axis. Recently, we have discovered that the enteric nervous system (ENS) is implicated in the maintenance of glycemia in the whole body *via* the brain. One of the main functions of ENS is to regulate contractions of intestinal smooth muscle cells. In physiological conditions, the reduction of intestinal contractions provokes a decreased fed hyperglycemia ([@B40]; [@B2]). The modifications of mechanical contractions are detected by the hypothalamus, which controls glucose utilization ([@B40]). During T2D, intestinal inflammation is clearly associated with a dysfunction of ENS neurons ([@B45]), which could favor duodenal hyper-contractility ([@B2]). Our group has demonstrated that duodenal hyper-contractility participates to the establishment of hyperglycemia of HFD mice by modulating the hypothalamic NO release ([@B40]).

Numerous pathologies that link inflammation, gut microbiota and ENS have been described ([@B47]). Along those lines, recent data have shown that specific neurodegenerative diseases (i.e., multiple sclerosis, Parkinson disease) were also characterized by gastrointestinal comorbidities. In these patients, the specific alterations in gut motility and other pre-motor symptoms are linked with changes in the gut microbiota composition and activity ([@B34]). Whether the couple microbiota and metabolites influencing the intestinal neuronal system may explain the onset of the disease remains to be proven, but it is becoming clear that the ENS can be considered as a cellular target to treat inflammatory diseases (T2D, inflammatory bowel diseases and ulcers).

Therefore, targeting the intestinal inflammation and/or the gut microbiota to restore the glucose and mechano-sensors in type 2 diabetic patients presents a real potential of scientific interest, but remains to be determined.

How the Inflammation Modulates the Enteric Nervous System?
==========================================================

Environmental changes related to the inflammatory processes that include a large spectrum of innate and adaptive immune responses, may affect ENS including myenteric plexus controlling gut motility ([@B24]).

Intestinal motility is regulated by ENS that includes intrinsic primary afferent neurons (IPAN), interneurons and choline acetyltransferase (ChAT)-producing excitatory and NO synthase (NOS)-producing inhibitory motor neurons ([@B1]). In the context of immune-mediated regulation of intestinal motility, *muscularis* macrophages residing in the myenteric plexus have been largely studied ([@B59]; [@B63]; [@B30]). However, cytokines, proteases or neuropeptides produced by mucosal immune cells may also modulate the activity of sensory neurons.

IPANs with their axons extending throughout intestinal mucosa and their cell bodies connected with interneurons which synapse with motor neurons may thus constitute central players in the immune-modulation of the intestinal motility. Accordingly, inflammatory cytokines including TNF-α, IL-1β or IL-6 as well as neuromediators released by innate and adaptive immune cells upon intestinal inflammation alter intrinsic and extrinsic enteric sensory neuron activities ([@B52]; [@B10]; [@B12]; [@B14]; [@B16]; [@B50]; [@B58]). A slower small-bowel transit and reduced smooth muscle contractility have been reported in patients with inflammatory bowel diseases ([@B67]; [@B58]). In experimental colitis, intestinal motility is either enhanced or reduced depending on the Th1 or Th2 types of inflammation. Th2-driven colitis induces smooth muscle hyper-contractility and augments intestinal transit while Th1-driven colitis is rather associated with hypo-contractility and reduced intestinal transit ([@B90]; [@B76]). Moreover, chronic intestinal inflammation often results in increased innervation together with a reduction of the neuronal activation threshold ([@B85]; [@B14]). The expression of TNF-α receptors (TNFR1, TNFR2) on enteric neurons also suggest that the neuronal activity maybe modulated directly by the inflammatory environment ([@B26]; [@B46]). Actually, TNF-α has the capacity to modulate electrophysiologic properties of neurons *via* a potentiating effect by increasing the action of cholinergic agonists (carbachol) on gut motility ([@B70]). This property of TNF-α could explain the negative impact of cytokines on gut motility. In a molecular point of view, the effect of TNF-α is mediated by an upregulation of the Cyclo-Oxygenase (COX-2), which in turn increases the production of an arachidonic acid derived-molecule, Thromboxane A2 (TXA~2~) ([@B69]). In experimental colitis, [@B26] have also demonstrated that TNF-α has an effect on the apoptosis rate of enteric neurons. Treatment with TNF inhibitors provokes a significant decrease of inflammatory markers expression such as inducible NOS (iNOS). IL-1β is another cytokine that has its receptors on ENS neurons ([@B46]). Similarly to TNF-α, IL-1β may increase iNOS mRNA expression in myenteric neurons ([@B82]). IL-1β could increase excitability of neurons by directly acting through its receptors expressed on cell surface. Mechanisms of IL-1β including depolarization of the membrane potential, decreased membrane conductance, and increased discharge of action potentials could explain the diarrhea phase, which appears in obese/diabetic patient ([@B3]) or during intestinal inflammation ([@B89]).

In addition to neurons, the ENS is composed of glial cells that exert a crucial role in intestinal physiology. Suppression of glial cells alters the function of ENS neurons with an increase in excitatory ChAT neurons and a decrease in inhibitory NOS neurons ([@B8]). Glial cells are exposed to various molecules depending on the environment including immune factors. Proinflammatory cytokines such as IL-1β and/or low IL-10 concentrations have the capacity to block glial cells proliferation ([@B72]), highlighting links between immune system and enteric nervous system. Moreover, IL-1β has also the capacity to regulate secretory functions of glial cells by increasing IL-6 synthesis and secretion ([@B73]). In turn, IL-6 may modulate T cell apoptosis or control gut motility to delay gastric emptying ([@B7]; [@B53]).

Summary/Conclusion
==================

T2D is associated with modification of the gut physiology including alterations of the function of immune cells and ENS. The crosstalk between the two partners is under the influence of the gut bacteria, which release bioactive factors that could participate as intermediate signaling molecules. Some evidence suggests that the establishment of T2D phenotypes (i.e., hyperglycemia, insulin resistance) may have a potential enteric origin; this is also the case of some neurological disorders (e.g., multiple sclerosis, Parkinson disease, autism). Deciphering the impact of "immune cells-ENS" communication and its impact on "gut-brain" axis could represent a new therapeutic perspective for diabetic patients (**Figure [1](#F1){ref-type="fig"}**). Therapeutic strategies have to take into account the importance of intestinal inflammation and its consequence on integrity of ENS. The gut microbiota and its bioactive releasing factors could represent one potential solution.

![Modulation of the enteric nervous system activity by intestinal immune system may impact on glycemia regulation. Most microbiota-derived products activate both epithelial cells and innate immune cells through pathogen recognition receptors such as toll-like receptors. They also initiate, mainly *via* microbe sampling through M(icrofold) cells, an adaptive immune response. This physiological immune response against intestinal flora generating pro-inflammatory effector T lymhocytes is tighly regulated by regulatory T lymphocytes which induction is associated with the production of short chain fatty acids (SCFAs) by commensal bacteria. Failure of the immune homeostasis may result in the release of higher amounts of proinflammatory cytokines including TNFα, IL1-β, IL6, IFNγ which, in turn, modulate either directly or through glial cells, enteric nervous system (ENS) activity. These alterations of the ENS contribute to impair gut-brain-peripheral axis leading to hyperglycemia and insulin-resistance.](fnins-12-00725-g001){#F1}
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